clinical trial · NCT07215273
Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy
Elion Therapeutics, Inc.·phase2·recruiting·n = 60
Invasive Mould InfectionEL219Active Comparator- IV Antifungal (LAmB or voriconazole)
brief summary
The purpose of this study is to determine if EL219 is safe and effective compared to liposomal amphotericin B (LAmB) or voricanozole for early treatment of invasive mould infections
started
Feb 13, 2026
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Sep 16, 2026
detailed description
A Phase 2, multicenter, randomized, double-blind Study of Safety and Efficacy of EL219 versus Comparator (LAmB or voriconazole) for early antifungal therapy of suspected or confirmed Invasive Mould Infections (IMI)
official title
A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 (Turletricin) Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections (TREAT-1)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol